Search results
2 dni temu · ATLANTA, October 16, 2024--Alzamend Neuro Announces Full Data Set from Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s
2 dni temu · Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“Alzheimer’s”), bipolar disorder (“BD”), major depressive disorder (“MDD”) and post-traumatic stress disorder (“PTSD”), today announced that it has received the final full data set from its multiple ...
2 dni temu · Based on the results from this study, Alzamend plans to initiate five clinical trials to determine relative increased lithium levels in the brain compared to a marketed lithium salt for healthy subject and patients diagnosed with mild to moderate Alzheimer’s, BD, MDD and PTSD, based on published mouse studies that predict that lithium can be ...
2 dni temu · On Wednesday, Alzamend Neuro, Inc. (NASDAQ:ALZN) said it received the final full data set from its multiple ascending dose clinical trial for AL001 for dementia related to Alzheimer's. Preliminary ...
3 dni temu · Building on the promising preliminary results released in June 2023, Alzamend’s full data set confirms the successful determination of a maximum tolerated dose (“MTD”) for AL001.
3 dni temu · Building on the promising preliminary results released in June 2023, Alzamend’s full data set confirms the successful determination of a maximum tolerated dose (“ MTD ”) for AL001. Identified by an independent safety review committee, this MTD represents a pivotal step forward; it delivers lithium at a lithium carbonate equivalent dose of ...
10 paź 2024 · Alzamend strives to provide hope through the commercialization of existing patented intellectual properties and know-how while simultaneously funding future treatments for other neurodegenerative diseases and psychiatric disorders, through advanced research and development.
